Диагностика местного рецидива после радикальной простатэктомии


Цитировать

Полный текст

Аннотация

Об авторах

Р И Гуспанов

РМАПО

Email: doctorren@mail.ru
Кафедра урологии и хирургической андрологии (зав. - член-корр. РАМН, проф., д-р мед. наук О. Б. Лоран), аспирант каф; РМАПО

А Обейд

РМАПО

Кафедра урологии и хирургической андрологии (зав. - член-корр. РАМН, проф., д-р мед. наук О. Б. Лоран); РМАПО

В Е Охриц

РМАПО

Кафедра урологии и хирургической андрологии (зав. - член-корр. РАМН, проф., д-р мед. наук О. Б. Лоран); РМАПО

R I Guspanov

A Obeid

V E Okhrits

Список литературы

  1. Lange P. H., Ercole C. J., Lightner D. J. et al. The value of serum prostate specific antigen determination before and after radical prostatectomy. J. Urol. (Baltimore) 1989; 141: 873-879.
  2. Amling C. L., Bergstralh E. J., Blute M. L. et al. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cutpoint? J. Urol. (Baltimore) 2001; 165: 1146.
  3. Freedland S. J., Sutter M. E., Dorey F., Aronson W. J. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Urology 2003; 61: 365-369.
  4. Moul J. W. Prostate specific antigen only progression of prostate cancer. J. Urol. (Baltimore) 2000; 163: 1632-1642.
  5. Neulander E. Z., Soloway M. S. Failure afterradical prostatectomy. Urology 2003; 61: 30-36.
  6. Partin A. W., Pearson J. D., Landis P. K. et al. Evaluation of prostate specific antigen velocity after radical prostatectomy to distinguish local recurrence versus distant metastases. Urology 1994; 43: 649-659.
  7. Patel A., Dorey F., Franklin J., DeKernion J. B. Recurrence pattern after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J. Urol. (Baltimore) 1997; 158: 1441-1445.
  8. Saleem M. D., Sanders H., Abu El Naser M., El-Galley R. Factors predicting cancer detection in biopsy of the prostatic fossa after radical prostatectomy. Urology 1998; 51: 283-286.
  9. Pound C. R., Christens Q. W., Gurganus R. et al. Digital rectal examination and imaging are unnecessary in men with undetectable prostate specific antigen following radical prostatectomy. J. Urol. (Baltimore) 1999; 162: 1337-1340.
  10. Obek C., Neulander E., Sadek S., Soloway M. Is there a role for digital examination in the followup of patients after radical prostatectomy? J. Urol. (Baltimore) 1999; 162: 762-764.
  11. Leventis A. K., Shariat S. F., Slawin K. M. Local recurrence after radical prostatectomy. Correlation of US features with prostatic fossa biopsy findings. Radiology 2001; 219: 432-439.
  12. Scattoni V., Roscigno M., Raber M. et al. Biopsy of the vesico-urethral anastomosis after radical prostatectomy: when and how. Eur. Urol. 2002; 38(Suppl I): 89-95.
  13. Shekarriz B., Upadhyay J., Wood D. P. Jr. et al. Vesicourethral anastomosis biopsy after radical prostatectomy. Predictive value of prostate-specific antigen and pathologic stage. Urology 1999; 54: 1044-1048.
  14. Connolly J. A., Shinohara K., Presti J. C. Jr., Carroll P. R. Local recurrence after radical prostatectomy: characteristics in size, location, and relationship to prostate-specific antigen and surgical margins. Urology 1996, 47: 225-231.
  15. Sodee D. B., Conant R., Chalfant M. et al. Preliminary imaging results using In-111 labeled CYT-356 (ProstaScint) in the detevtion of recurrent prostate cancer. Clin. Nucl. Med. 1996; 21: 759-767.
  16. Raj G. V., Partin A. W., Polascik T. J. Clinical utility of indium 111-capromab pendetide Immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy. Cancer 2002; 94: 987-996.
  17. Elgamal A. A., Troychak M. J., Murphy G. P. ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: analysis of 136 scans of 100 patients. Prostate 1998; 37: 261-269.
  18. Petronis J. D., Regan F., Lin K. Indium-111 capromab pendetide (ProstaScint) imaging to detect recurrent and metastatic prostate cancer. Clin. Nucl. Med. 1998; 23: 672-677.
  19. Hoh C. K., Schiepers C., Seltzer M. A. et al. PET in oncology: will it replace the other modalities? Semin. Nucl. Med. 1997; 27: 94-106.
  20. Hara T., Kosaka N., Kishi H. PET imaging of prostate cancer using carbon-11-choline. J. Nucl. Med. 1998; 39: 90-995.
  21. Picchio M., Messa C., Landoni C. et al. Value of [11C]Choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography. J. Urol. (Baltimore) 2003; 169: 1337-1340.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО «Бионика Медиа», 2011

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах